<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433030</url>
  </required_header>
  <id_info>
    <org_study_id>PHPT-Cohort</org_study_id>
    <nct_id>NCT00433030</nct_id>
  </id_info>
  <brief_title>Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand</brief_title>
  <official_title>Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since 2004, the Thai Ministry of Public Health has massively scaled up antiretroviral
      treatment programs to provide therapy to more than 80,000 patients with partial support of
      the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM).

      As access to HIV care continues to expand under the universal health coverage system, it is
      important to document and analyze the efficacy, tolerance, toxicity and acceptability of
      antiretroviral therapy within pilot treatment programs, to provide evidence based feedback
      and recommendations to the national program and policy makers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As Thailand is rapidly expanding access to antiretroviral treatments under the universal
      health coverage system, it is crucial to document and learn from pilot antiretroviral
      treatment programs, in particular the medical outcomes and logistical, and organizational
      issues faced by hospital teams and patients in order to adapt the ARV delivery and monitoring
      system to various local settings.

      Specific objectives

        1. Analyze data collected in patients participating in the PHPT antiretroviral treatment
           program, in accordance to national and international guidelines, with no experimental
           interventions.

        2. To determine factors associated with treatment outcome including immune status,
           virologic factors and antiretroviral drugs levels

        3. To study the operational aspects of integrating comprehensive HIV care into the existing
           care system with regards to new activities generated at the hospital level (counseling,
           referral systems, biological monitoring), the impact on other health activities,
           mobilization of human and financial resources, affordability and sustainability.

      The population of the study consists of approximately 2,000 consenting HIV-infected patients,
      including one-third of children, receiving HIV care as part of the GF-ATM or OXFAM Access to
      Antiretroviral programs, presenting at any of the PHPT network hospitals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">2816</enrollment>
  <condition>HIV Infections</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected Adults and Children
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults and children (children are defined as less than 18 years old) patients are
             eligible for the inclusion in the cohort if they meet all the following inclusion
             criteria:

               -  Participation in the GFATM or Oxfam Access to Antiretroviral Programs

               -  For adults, consent to have their clinical or biological data used for this
                  research study, and willingness to be followed at one of the PHPT network
                  hospitals. For children, caregiver's consent to participate, willingness to bring
                  the child to the scheduled visits for the duration of the treatment, and to have
                  the child's clinical or biological data used for this research study.

        Exclusion Criteria:

          -  This is an observational study of an access to treatment program, therefore all
             patients who require treatment and are willing to be followed by the medical team and
             have their data collected can be enrolled in the study. The only exclusion criteria
             would be refusal to participate and the discontinuation criteria would be withdrawal
             of consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gonzague JOURDAIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Doi Saket Hospital</name>
      <address>
        <city>Doi Saket</city>
        <state>Chiang Mai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mae on Hospital</name>
      <address>
        <city>Mae on</city>
        <state>Chiang Mai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakornping Hospital</name>
      <address>
        <city>Mae Rim</city>
        <state>Chiang Mai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Kamphaeng Hospital</name>
      <address>
        <city>San Kamphaeng</city>
        <state>Chiang Mai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanpatong Hospital</name>
      <address>
        <city>San Pa Tong</city>
        <state>Chiang Mai</state>
        <zip>50120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Sai Hospital</name>
      <address>
        <city>San Sai</city>
        <state>Chiang Mai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mae Chan Hospital</name>
      <address>
        <city>Mae Chan</city>
        <state>Chiang Rai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mae Sai Hospital</name>
      <address>
        <city>Mae Sai</city>
        <state>Chiang Rai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phan Hospital</name>
      <address>
        <city>Phan</city>
        <state>Chiang Rai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <state>Chiangrai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somdej Pranangchao Sirikit Hospital</name>
      <address>
        <city>Sattahip</city>
        <state>Chonburi</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kranuan Crown Prince Hospital</name>
      <address>
        <city>Kranuan</city>
        <state>Khon Kaen</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahasarakam Hospital</name>
      <address>
        <city>Maha Sarakham</city>
        <state>Mahasarakam</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakhonpathom Hospital</name>
      <address>
        <city>Nakhon Pathom</city>
        <state>Nakhonpathom</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Kham Hospital</name>
      <address>
        <city>Chiang Kham</city>
        <state>Phayao</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hat Yai Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhumibol Adulyadej Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nopparat Rajathanee Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somdej Prapinklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chacheongsao Hospital</name>
      <address>
        <city>Chachoengsao</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prapokklao Hospital</name>
      <address>
        <city>Chanthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonburi Hospital</name>
      <address>
        <city>Chon Buri</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalasin Hospital</name>
      <address>
        <city>Kalasin</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phaholpolphayuhasena Hospital</name>
      <address>
        <city>Kanchanaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Health Promotion Centre 6, Khon Kaen</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lampang Hospital</name>
      <address>
        <city>Lampang</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lamphun Hospital</name>
      <address>
        <city>Lamphun</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakornratchasrima Hospital</name>
      <address>
        <city>Nakhon Ratchasima</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nong Khai Hospital</name>
      <address>
        <city>Nong Khai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pranangklao Hospital</name>
      <address>
        <city>Nonthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phayao Provincial Hospital</name>
      <address>
        <city>Phayao</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhachinaraj Hospital</name>
      <address>
        <city>Phitsanulok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ratchaburi Hospital</name>
      <address>
        <city>Ratchaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rayong Hospital</name>
      <address>
        <city>Rayong</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roi-et Hospital</name>
      <address>
        <city>Roi-et</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutprakarn Hospital</name>
      <address>
        <city>Samut Prakan</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutsakon Hospital</name>
      <address>
        <city>Samut Sakhon</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.phpt.org/cohort-of-hiv-infected-adults-and-children.html</url>
    <description>PHPT Antiretroviral Treatment Cohorts</description>
  </link>
  <results_reference>
    <citation>Collins IJ, Jourdain G, Hansudewechakul R, Kanjanavanit S, Hongsiriwon S, Ngampiyasakul C, Sriminiphant S, Technakunakorn P, Ngo-Giang-Huong N, Duong T, Le Coeur S, Jaffar S, Lallemant M; Program for HIV Prevention and Treatment Study Team. Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis. 2010 Dec 15;51(12):1449-57. doi: 10.1086/657401. Epub 2010 Nov 5.</citation>
    <PMID>21054181</PMID>
  </results_reference>
  <results_reference>
    <citation>Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis. PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.</citation>
    <PMID>22132100</PMID>
  </results_reference>
  <results_reference>
    <citation>Jourdain G, Wagner TA, Ngo-Giang-Huong N, Sirirungsi W, Klinbuayaem V, Fregonese F, Nantasen I, Techapornroong M, Halue G, Nilmanat A, Wittayapraparat P, Chalermpolprapa V, Pathipvanich P, Yuthavisuthi P, Frenkel LM, Lallemant M; Program for HIV Prevention and Treatment (PHPT) Study Group. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis. 2010 May 15;50(10):1397-404. doi: 10.1086/652148.</citation>
    <PMID>20377404</PMID>
  </results_reference>
  <results_reference>
    <citation>Wagner TA, Kress CM, Beck I, Techapornroong M, Wittayapraparat P, Tansuphasawasdikul S, Jourdain G, Ngo-Giang-Huong N, Lallemant M, Frenkel LM. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol. 2010 May;48(5):1555-61. doi: 10.1128/JCM.02062-09. Epub 2010 Feb 24.</citation>
    <PMID>20181911</PMID>
  </results_reference>
  <results_reference>
    <citation>Fregonese F, Collins IJ, Jourdain G, Lecoeur S, Cressey TR, Ngo-Giang-Houng N, Banchongkit S, Chutanunta A, Techapornroong M, Lallemant M; Program for HIV Prevention and Treatment Study Group. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. J Acquir Immune Defic Syndr. 2012 May 1;60(1):91-8. doi: 10.1097/QAI.0b013e31824bd33f.</citation>
    <PMID>22293548</PMID>
  </results_reference>
  <results_reference>
    <citation>Duong T, Jourdain G, Ngo-Giang-Huong N, Le Cœur S, Kantipong P, Buranabanjasatean S, Leenasirimakul P, Ariyadej S, Tansuphasawasdikul S, Thongpaen S, Lallemant M; Program for HIV Prevention and Treatment Study Group. Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand. PLoS One. 2012;7(8):e43375. Epub 2012 Aug 15.</citation>
    <PMID>22905264</PMID>
  </results_reference>
  <results_reference>
    <citation>Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Luekamlung N, Halue G, Buranawanitchakorn Y, Kunkongkapan S, Buranabanjasatean S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment Study Group. Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand. PLoS One. 2012;7(7):e42184. Epub 2012 Jul 31.</citation>
    <PMID>22860080</PMID>
  </results_reference>
  <results_reference>
    <citation>Collins IJ, Cairns J, Jourdain G, Fregonese F, Nantarukchaikul M, Lertpienthum N, Wannarit P, Attavinijtrakarn P, Layangool P, Le Coeur S, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study team. Hospitalization trends, costs, and risk factors in HIV-infected children on antiretroviral therapy. AIDS. 2012 Sep 24;26(15):1943-52.</citation>
    <PMID>22824633</PMID>
  </results_reference>
  <results_reference>
    <citation>Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; HIV-NAT 086Study Team. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x. Epub 2010 Mar 25.</citation>
    <PMID>20345882</PMID>
  </results_reference>
  <results_reference>
    <citation>Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br J Clin Pharmacol. 2012 Dec;74(6):1005-12. doi: 10.1111/j.1365-2125.2012.04288.x.</citation>
    <PMID>22471906</PMID>
  </results_reference>
  <results_reference>
    <citation>Puthanakit T, Jourdain G, Suntarattiwong P, Chokephaibulkit K, Siangphoe U, Suwanlerk T, Prasitsuebsai W, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Waranawat N, Ananworanich J; HIV-NAT 086 study team. High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting. AIDS Res Ther. 2012 Jun 18;9(1):20. doi: 10.1186/1742-6405-9-20.</citation>
    <PMID>22709957</PMID>
  </results_reference>
  <results_reference>
    <citation>Collins I, Cairns J, Le Coeur S, Pagdi K, Ngampiyaskul C, Layangool P, Borkird T, Na-Rajsima S, Wanchaitanawong V, Jourdain G, Lallemant M. Five-year trends in antiretroviral usage and drug costs in HIV-infected children in Thailand. J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):95-102. doi: 10.1097/QAI.0b013e318298a309.</citation>
    <PMID>23945253</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.</citation>
    <PMID>23687292</PMID>
  </results_reference>
  <results_reference>
    <citation>Collins IJ, Cairns J, Ngo-Giang-Huong N, Sirirungsi W, Leechanachai P, Le Coeur S, Samleerat T, Kamonpakorn N, Mekmullica J, Jourdain G, Lallemant M; Programme for HIV Prevention and Treatment Study Team. Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in Thailand. PLoS One. 2014 Mar 14;9(3):e91004. doi: 10.1371/journal.pone.0091004. eCollection 2014.</citation>
    <PMID>24632750</PMID>
  </results_reference>
  <results_reference>
    <citation>Suaysod R, Ngo-Giang-Huong N, Salvadori N, Cressey TR, Kanjanavanit S, Techakunakorn P, Krikajornkitti S, Srirojana S, Laomanit L, Chalermpantmetagul S, Lallemant M, Le Cœur S, McIntosh K, Traisathit P, Jourdain G. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy. Clin Infect Dis. 2015 Jul 1;61(1):95-101. doi: 10.1093/cid/civ271. Epub 2015 Apr 1.</citation>
    <PMID>25838288</PMID>
  </results_reference>
  <results_reference>
    <citation>Riyaten P, Salvadori N, Traisathit P, Ngo-Giang-Huong N, Cressey TR, Leenasirimakul P, Techapornroong M, Bowonwatanuwong C, Kantipong P, Nilmanat A, Yutthakasemsunt N, Chutanunta A, Thongpaen S, Klinbuayaem V, Decker L, Le Cœur S, Lallemant M, Capeau J, Mary JY, Jourdain G. New-Onset Diabetes and Antiretroviral Treatments in HIV-Infected Adults in Thailand. J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):453-9. doi: 10.1097/QAI.0000000000000647.</citation>
    <PMID>25886928</PMID>
  </results_reference>
  <results_reference>
    <citation>Traisathit P, Delory T, Ngo-Giang-Huong N, Somsamai R, Techakunakorn P, Theansavettrakul S, Kanjanavanit S, Mekmullica J, Ngampiyaskul C, Na-Rajsima S, Lallemant M, Cressey TR, Jourdain G, Collins IJ, Le Coeur S. Brief Report: AIDS-Defining Events and Deaths in HIV-Infected Children and Adolescents on Antiretrovirals: A 14-Year Study in Thailand. J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):17-22. doi: 10.1097/QAI.0000000000001571.</citation>
    <PMID>29040162</PMID>
  </results_reference>
  <results_reference>
    <citation>Delory T, Ngo-Giang-Huong N, Rangdaeng S, Chotivanich N, Limtrakul A, Putiyanun C, Suriyachai P, Matanasarawut W, Jarupanich T, Liampongsabuddhi P, Heard I, Jourdain G, Lallemant M, Le Coeur S; PapilloV study group. Human Papillomavirus infection and cervical lesions in HIV infected women on antiretroviral treatment in Thailand. J Infect. 2017 May;74(5):501-511. doi: 10.1016/j.jinf.2017.02.007. Epub 2017 Feb 28.</citation>
    <PMID>28254419</PMID>
  </results_reference>
  <results_reference>
    <citation>Salvadori N, Ngo-Giang-Huong N, Duclercq C, Kanjanavanit S, Ngampiyaskul C, Techakunakorn P, Puangsombat A, Figoni J, Mary JY, Collins IJ, Cressey TR, Le Cœur S, Sirirungsi W, Lallemant M, McIntosh K, Jourdain G. Incidence of Tuberculosis and Associated Mortality in a Cohort of Human Immunodeficiency Virus-Infected Children Initiating Antiretroviral Therapy. J Pediatric Infect Dis Soc. 2017 Jun 1;6(2):161-167. doi: 10.1093/jpids/piw090.</citation>
    <PMID>28204517</PMID>
  </results_reference>
  <results_reference>
    <citation>Homkham N, Cressey TR, Ingsrisawang L, Bouazza N, Ngampiyaskul C, Hongsiriwon S, Srirojana S, Kanjanavanit S, Bhakeecheep S, Coeur SL, Salvadori N, Treluyer JM, Jourdain G, Urien S. A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based Regimens. J Clin Pharmacol. 2016 Sep;56(9):1076-83. doi: 10.1002/jcph.701. Epub 2016 Feb 24.</citation>
    <PMID>26749102</PMID>
  </results_reference>
  <results_reference>
    <citation>European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand. Antivir Ther. 2016;21(4):353-8. doi: 10.3851/IMP3008. Epub 2015 Nov 12.</citation>
    <PMID>26561496</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2007</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherche pour le Developpement</investigator_affiliation>
    <investigator_full_name>GONZAGUE JOURDAIN</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>Highly Active Antiretroviral Therapy</keyword>
  <keyword>HIV Viral load</keyword>
  <keyword>HIV drug Resistance</keyword>
  <keyword>Thailand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

